Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model

References

• Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017 Feb;17(1):65–70.
   PubMed Web of Science ®Google Scholar
• Colbert RA, Ward MM. JAK inhibitors taking on psoriatic arthritis. N Engl J Med. 2017 Oct 19;377(16):1582–1584.
   PubMed Web of Science ®Google Scholar
• Olivieri I, D’Angelo S, Palazzi C, et al. Pharmacoeconomic issues in psoriatic arthritis. J Rheumatol Suppl. 2012 Jul;89:103–105.
   PubMedGoogle Scholar
• Da Silva MRR, JBR DS, Almeida AM, et al. Access to high-cost medications for psoriatic arthritis in the national health system in Brazil: the long path up to dispensation. Adv Rheumatol. 2019 Nov 14;59(1):48.
   PubMedGoogle Scholar
• Guerra Junior AA, Pereira RG, Andrade EIG, et al. Building the national database of health centred on the individual: administrative and epidemiological record linkage - Brazil, 2000–2015. Int J Popul Data Sci. 2018;3(1):20.
   Google Scholar
• Da Silva MRR, JBR DS, Almeida AM, et al. Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. Expert Rev Clin Immunol. 2019;15(8):879–887.
   PubMed Web of Science ®Google Scholar
• Ribeiro da Silva MR, Ribeiro Dos Santos JB, Maciel Almeida A, et al. Medication persistence for psoriatic arthritis in a Brazilian real-world setting. Future Sci OA. 2019 Jan 18;5(2):FSO369.
   PubMed Web of Science ®Google Scholar
• da Silva MRR, Dos Santos JBR, Almeida AM, et al. Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis. J Comp Eff Res. 2018;7(10):989–1000.
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.
   PubMed Web of Science ®Google Scholar
• Van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept Study 314 Investigators. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65(12):1572–1577.
   PubMed Web of Science ®Google Scholar
• Da Silva MRR Pharmacoepidemiological and pharmacoeconomic analysis of tumor necrosis factor inhibitor drugs for the treatment of psoriatic arthritis in the unified health system [dissertation]. Belo Horizonte (MG): Federal University of Minas Gerais; 2019. Available from: https://repositorio.ufmg.br/bitstream/1843/33776/1/Tese_impressao_final_capa_dura.pdf.
   Google Scholar
• Taylor WJ, Helliwell PS. Development of diagnostic criteria for psoriatic arthritis: methods and process. Curr Rheumatol Rep. 2004;6(4):299–305.
   PubMedGoogle Scholar
• Wong PC, Leung YY, Li EK, et al. Measuring disease activity in psoriatic arthritis. Int J Rheumatol. 2012;2012:839425.
   PubMedGoogle Scholar
• Acosta Felquer ML, Ferreyra Garrott L, Marin J, et al. Remission criteria and activity indices in psoriatic arthritis. Clin Rheumatol. 2014 Sep;33(9):1323–1330.
   PubMed Web of Science ®Google Scholar
• Michelsen B, Sexton J, Smolen JS, et al. Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for Psoriatic Arthritis (DAPSA) based on 28 joints? Ann Rheum Dis. 2018 Dec;77(12):1736–1741.
   PubMed Web of Science ®Google Scholar
• Brazilian Ministry of Health. Clinical protocol and therapeutic guidelines to psoriatic arthritis in Brazil. 2020 [cited 2020 Nov 25]. Available from: http://conitec.gov.br/images/Consultas/Relatorios/2020/20201123_Relatorio_PCDT-ArtritePsoriaca_550.pdf.
   Google Scholar
• Dos Santos JBR, da Silva MRR, Almeida AM, et al. Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert Rev Pharmacoecon Outcomes Res. 2020 Nov;2:1–6.
   Google Scholar
• Viegas Andrade M, Noronha K, Kind P, et al. Societal preferences for EQ-5D health states from a brazilian population survey. Value Health Reg Issues. 2013 Dec;2(3):405–412.
   PubMedGoogle Scholar
• Dos Santos JBR, Guerra Junior AA, da Silva MRR, et al. First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert Rev Clin Pharmacol. 2019 Apr;12(4):363–370.
   PubMed Web of Science ®Google Scholar
• Acurcio FA, Guerra AA Junior, da Silva MRR, et al. Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Curr Med Res Opin. 2020 Apr;36(4):677–686.
   PubMed Web of Science ®Google Scholar
• Dos Santos JBR, da Silva MRR, Kakehasi AM, et al. First line of subcutaneous anti-tnf therapy for rheumatoid arthritis: a prospective cohort study. Expert Rev Clin Immunol. 2020 Dec 15;16(12):1217–1225.
   PubMed Web of Science ®Google Scholar
• Brazilian Ministry of Health. Methodological guidelines: economic assessment guideline. 2 ed. Brasília (DF): 2014. p. 132. Health Ministry. Available from: <http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_diretriz_avaliacao_economica.pdf>
   Google Scholar
• Edlin R. Cost effectiveness modelling for health technology assessment: a practical course. Adis. 2015. DOI:https://doi.org/10.1007/978-3-319-15744-3
   Google Scholar
• World Bank, International Comparison Program database. GDP per capita, PPP (current international $) – brazil. 2019 [cited 2020 Nov 25]. Available from: <https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD?locations=BR>.
   Google Scholar
• Yang TS, Chi CC, Wang SH, et al. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system. Int J Rheum Dis. 2016;19(10):1002–1009.
   PubMed Web of Science ®Google Scholar
• Cawson MR, Mitchell SA, Knight C, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord. 2014 Jan;20(15):26.
   Google Scholar
• Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15(10):i–xxi, 1–329.
   Web of Science ®Google Scholar
• Purmonen T, Puolakka K, Bhattacharyya D, et al. Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective. Cost Eff Resour Alloc. 2018;16:56.
   PubMed Web of Science ®Google Scholar
• Scheinberg MA, Felix PAO, Kos IA, et al. Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market. Einstein (Sao Paulo). 2018 Sep 17;16(3):eRW4175.
   PubMed Web of Science ®Google Scholar
• Pimenta MV, Monteiro G. The production of biopharmaceuticals in Brazil: current issues. Braz J Pharm Sci. 2019;55:e17823.
   Web of Science ®Google Scholar
• Corbett M, Chehadah F, Biswas M, et al. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 2017 Oct;21(56):1–326.
   Web of Science ®Google Scholar